Laurène Cagnon

2.2k citations

18 papers · 1.7k indexed · 1 hit paper · h-index 16

Co-authors: Olivier Braissant Daniel E. Speiser Petra Baumgaertner Nicole Montandon Olivier Michielin Emanuela Romano Carla Costa-Nunes Christiane Meyer
Topics: Immunotherapy and Immune Responses (7 papers)Cancer Immunotherapy and Biomarkers (5 papers)CAR-T cell therapy research (3 papers)
Cited by: Endocrine and Autonomic Systems Immunology Oncology
Journals: Clinical Cancer Research Journal of Medicinal Chemistry Science Translational Medicine
Partner nations: Switzerland United States France

In The Last Decade

Laurène Cagnon

18 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

2013 450 citations Christiane Meyer, Laurène Cagnon et al. Cancer Immunology Immunotherapy profile →

Peers

Countries citing papers authored by Laurène Cagnon

Since Specialization

Citations

This map shows the geographic impact of Laurène Cagnon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurène Cagnon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurène Cagnon more than expected).

Fields of papers citing papers by Laurène Cagnon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurène Cagnon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurène Cagnon. The network helps show where Laurène Cagnon may publish in the future.

Co-authorship network of co-authors of Laurène Cagnon

This figure shows the co-authorship network connecting the top 25 collaborators of Laurène Cagnon. A scholar is included among the top collaborators of Laurène Cagnon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurène Cagnon. Laurène Cagnon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry 2018 ·Journal of Chromatography B ·(unknown),Thomas Mercier,Dorothea Wagner,Krisztián Homicskó,Olivier Michielin,(unknown),Laurène Cagnon,Manuel Diezi,Thierry Buclin,Nicolas Widmer,Chantal Csajka,Laurent A. Décosterd	33
2	Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity 2018 ·Frontiers in Oncology ·Pelagia Tsoutsou,Khalil Zaman,Silvia Martin Lluesma,Laurène Cagnon,Lana E. Kandalaft,Marie‐Catherine Vozenin	15
3	Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients 2016 ·Clinical Cancer Research ·Philippe O. Gannon,Petra Baumgaertner,Alexandre Huber,Emanuela M. Iancu,Laurène Cagnon,Samia Abed Maillard,Hélène Maby–El Hajjami,Daniel E. Speiser,Nathalie Rufer	19
4	Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients 2016 ·Frontiers in Immunology ·T. J. Murray,Silvia A. Fuertes Marraco,Petra Baumgaertner,Natacha Bordry,Laurène Cagnon,Alena Donda,Pedro Romero,Grégory Verdeil,Daniel E. Speiser	82
5	Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8⁺ and CD4⁺ T-cell responses with multiple specificities including a novel DR7-restricted epitope 2016 ·OncoImmunology ·(unknown),(unknown),Amélie Cachot,Hélène Maby–El Hajjami,Laurène Cagnon,Marion Braun,Laurent Derré,(unknown),Donata Rimoldi,Sacha Gnjatic,Samia Abed Maillard,(unknown),Maria Pia Protti,Emanuela Romano,Olivier Michielin,Pablo Romero,Daniel E. Speiser,Camilla Jandus	47
6	Long-lasting stem cell–like memory CD8 ⁺ T cells with a naïve-like profile upon yellow fever vaccination 2015 ·Science Translational Medicine ·Silvia A. Fuertes Marraco,Charlotte Soneson,Laurène Cagnon,Philippe O. Gannon,Mathilde Allard,Samia Abed Maillard,Nicole Montandon,Nathalie Rufer,Sophie Waldvogel,Mauro Delorenzi,Daniel E. Speiser	149
7	Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial 2015 ·Clinical Cancer Research ·Amandine Legat,Hélène Maby–El Hajjami,Petra Baumgaertner,Laurène Cagnon,Samia Abed Maillard,Christine Geldhof,Emanuela M. Iancu,Luc Lebon,Philippe Guillaume,Danijel Dojcinovic,Olivier Michielin,Emanuela Romano,Grégoire Berthod,Donata Rimoldi,Frédéric Triebel,Immanuel F. Luescher,Nathalie Rufer,Daniel E. Speiser	76
8	Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope 2015 ·Journal for ImmunoTherapy of Cancer ·Petra Baumgärtner,(unknown),Amélie Cachot,Hélène Maby–El Hajjami,Laurène Cagnon,Marion Braun,Laurent Derré,Jean‐Paul Rivals,Donata Rimoldi,Emanuela Romano,Olivier Michielin,Pedro Romero,Camilla Jandus,Daniel E. Speiser	2
9	Pulmonary Sarcoid–like Granulomatosis after Multiple Vaccinations of a Long-term Surviving Patient with Metastatic Melanoma 2014 ·Cancer Immunology Research ·Natacha Bordry,(unknown),Laurène Cagnon,Philippe O. Gannon,Samia Abed‐Maillard,Petra Baumgaertner,T. J. Murray,Igor Letovanec,Romain Lazor,Hasna Bouchaab,Nathalie Rufer,Emanuela Romano,Olivier Michielin,Daniel E. Speiser	7
10	Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumabbreakdown → 2013 ·Cancer Immunology Immunotherapy ·Christiane Meyer,Laurène Cagnon,Carla Costa-Nunes,Petra Baumgaertner,Nicole Montandon,(unknown),Olivier Michielin,Emanuela Romano,Daniel E. Speiser	450
11	Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors 2011 ·Bioorganic & Medicinal Chemistry ·Francesca Gaggini,Benoı̂t Laleu,(unknown),(unknown),Laurène Cagnon,(unknown),(unknown),(unknown),Cédric Merlot,Freddy Heitz,Cédric Szyndralewiez,Patrick Page	67
12	Methods to Assess Neuroinflammation 2011 ·Current Protocols in Toxicology ·Florianne Monnet‐Tschudi,(unknown),Olivier Braissant,Laurène Cagnon,Marie‐Gabrielle Zurich	25
13	First in Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis 2010 ·Journal of Medicinal Chemistry ·Benoı̂t Laleu,Francesca Gaggini,(unknown),(unknown),Laurène Cagnon,(unknown),(unknown),(unknown),Cédric Merlot,Freddy Heitz,Cédric Szyndralewiez,Patrick Page	207
14	Ammonium alters creatine transport and synthesis in a 3D culture of developing brain cells, resulting in secondary cerebral creatine deficiency 2008 ·European Journal of Neuroscience ·Olivier Braissant,Laurène Cagnon,Florianne Monnet‐Tschudi,Oliver Speer,Theo Wallimann,Paul Honegger,Hugues Henry	49
15	CNTF protects oligodendrocytes from ammonia toxicity: Intracellular signaling pathways involved 2008 ·Neurobiology of Disease ·Laurène Cagnon,Olivier Braissant	25
16	Role of caspases, calpain and cdk5 in ammonia-induced cell death in developing brain cells 2008 ·Neurobiology of Disease ·Laurène Cagnon,Olivier Braissant	26
17	Hyperammonemia-induced toxicity for the developing central nervous system 2007 ·Brain Research Reviews ·Laurène Cagnon,Olivier Braissant	94
18	A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep 2003 ·BMC Neuroscience ·Laure Verret,Romain Goutagny,Patrice Fort,Laurène Cagnon,Denise Salvert,Lucienne Léger,Romuald Boissard,Paul Salin,Christelle Peyron,Pierre‐Hervé Luppi	322

About Laurène Cagnon

Laurène Cagnon is a scholar working on Immunology, Clinical Biochemistry and Neurology, having authored 18 papers that have together received 1.7k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Endocrine and Autonomic Systems (289 citations), Immunology (809 citations) and Oncology (625 citations). Laurène Cagnon has collaborated with scholars based in Switzerland, United States and France. Frequent co-authors include Olivier Braissant, Daniel E. Speiser, Petra Baumgaertner, Nicole Montandon, Olivier Michielin, Emanuela Romano, Carla Costa-Nunes, Christiane Meyer, Pierre‐Hervé Luppi and Romuald Boissard. Their work appears in journals such as Clinical Cancer Research, Journal of Medicinal Chemistry and Science Translational Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact